Company intelligence / Profile preview
Hebei Wanbang Fulin Pharmaceutical
Hebei, Chinafolon.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company is approved for and markets Xihuang Capsules, an herbal medicine primarily for abscesses and possibly other indications, approved in China since April 2020. No published data on additional programs or broader pipeline.
- Therapeutic areas
- Infectious DiseasesOther
- Modalities
- Herbal medicine
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Hebei Wanbang Fulin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hebei Wanbang Fulin Pharmaceutical.